Aptevo Therapeutics APVO

Aptevo announces platform presentation at SITC 2026

Form
8-K
Filed
Importance
Routine
  1. Presenting at SITC 2026 Annual Meeting, Nov 4-8, 2026
  2. Showcasing multispecific platform targeting tumor microenvironment
  3. CD40-directed molecules aim to enhance immune response
  4. Presentation details include abstract number 1,060

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Get an email when Aptevo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.